Holen Sie sich die Stockscreener-App
1.8659
1.79%
-0.0341
Handel nachbörslich:
1.88
0.0141
+0.76%
Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten
CytoMed Therapeutics Limited Stock Analysis and ForecastMarket-leading growth rates - Autocar Professional
What drives CytoMed Therapeutics Limited stock priceExplosive market performance - jammulinksnews.com
Is CytoMed Therapeutics Limited a good long term investmentRapid-fire capital growth - jammulinksnews.com
How high can CytoMed Therapeutics Limited stock price go in 2025Daily Swing Candidates - Newser
What drives SDST stock priceConsistently profitable trades - Autocar Professional
The ANGELICA Trial and the Future of Allogeneic CAR-T: A Strategic Investment Perspective - AInvest
CytoMed's Breakthrough Cancer Cell Therapy Shows Promise in Phase 1 Trial, Advances to Higher Dose Testing - Stock Titan
GDTC advances CTM-N2D: Dose Level 1 complete, Phase I escalates | GDTC SEC FilingForm 6-K - Stock Titan
COST Stock Analysis and ForecastFree Investment Community - jammulinksnews.com
Blue Chip Stocks High Precision Stock TipsBreakthrough stock performance - jammulinksnews.com
What analysts say about CytoMed Therapeutics Limited stockExceptional profit velocity - jammulinksnews.com
How CytoMed Therapeutics Limited stock performs during market volatilitySmart Money Trade Setups - Newser
What makes CytoMed Therapeutics Limited stock price move sharplySafe and Scalable Investment Tips - Newser
Why CytoMed Therapeutics Limited stock attracts strong analyst attentionTrade With Low Risk Exposure - Newser
CytoMed Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria
CytoMed Therapeutics shareholders approve all proposals at annual meeting - Investing.com
The Pipeline for of iPSC-Derived Cell Therapeutics in 2025 - BioInformant
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shel - GuruFocus
CytoMed Therapeutics Files $50 Million Mixed Shelf - MarketScreener
Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News - GuruFocus
CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia
CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India
CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World
CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript
CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire
CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan
BRIEF-CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025 - Yahoo.co
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight - The Globe and Mail
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire
CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com
SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare
SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India - Pharmabiz.com
CytoMed Partners with SunAct for Groundbreaking Cancer Cell Therapy Trial in India - Stock Titan
CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - simplywall.st
CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance
Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance
CytoMed Therapeutics Acquires Cord Blood Banking License and 12,000 CBUs; Will Develop Cord Blood-derived Biologics through It Subsidiary, LongevityBank - BioInformant
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Yahoo Finance
Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - GlobeNewswire
CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire
iPSC Applications in Cell Therapy, Drug Discovery, and Beyond - BioInformant
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire
Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration | Value Investing NewsInvestor powered stock market news - Financial Content
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire
GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView
Singapore-China collaboration to explore allogeneic gamma delta T cell technology for cancer treatment - BioSpectrum Asia
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire
CytoMed Expands Research Collaboration into China After Entering Into MOU - StreetInsider
Cytomed signs MOU to leverage CNK's Piggybac technology to permanently graft CARs into γδ T cells - BioWorld MedTech
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γD T In Vivo Persistency - BioSpace
CytoMed Therapeutics Rally Continues - Nasdaq
Singapore's CytoMed Therapeutics announces collaboration with MD Anderson Cancer Center in US - BioSpectrum Asia
CytoMed and MD Anderson partner to use gdTc for cancer treatment - Pharmaceutical Technology
CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering - PR Newswire
Peter Choo-backed biomed firm CytoMed lists on Nasdaq - The Edge Singapore
GDTCCytoMed Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan
CytoMed Therapeutics Limited Announces Pricing of Initial Public Offering - PR Newswire
IPO Update: CytoMed Therapeutics Aims For $11 Million U.S. IPO (Pending:GDTC) - Seeking Alpha
Malaysia-Singapore Collaborates In The Field Of Clinical Research - BusinessToday Malaysia
Compulsory vaccination: MOH prepared to hear views from all - thesun.my
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):